Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[2H9]-choline is a deuterium-labeled metabolic imaging probe used in deuterium magnetic resonance spectroscopy (DMRS) to assess phospholipid biosynthesis. It serves as a substrate for choline kinase α (CKα), which phosphorylates it into [2H9]-phosphocholine. Since CKα is frequently upregulated in cancers to support high membrane turnover, the conversion rate of [2H9]-choline provides a non-invasive readout of tumor metabolic activity and proliferation. Research at UCSF has demonstrated its utility in monitoring tumor burden and early therapeutic response in glioma models, where it can detect metabolic changes following temozolomide treatment before anatomical changes are visible on standard imaging.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [2H9]-choline.